Demant's divested hearing implant business was unprofitable in H1
Oticon Medical, which hearing aid manufacturer Demant sold off to Cochlear in April, booked a deficit of DKK 107m (USD 14.6m) in the first half year of 2022.
by albert rønning-andersson, translated by daniel pedersen
In April, when hearing aid group Demant announced its intention to sell its 15-year-old Hearing Implants business, also known as Oticon Medical, to Australian Cochlear, no one knew whether the business leg was running a profit or a loss.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Cochlear relieves Demant of loss-making implant division
For subscribers
